Non-inferiority study of ocrelizumab and rituximab in active multiple
Danish non-inferiority study of ocrelizumab and rituximab in MS (DanNORMS): A randomized study comparing the efficacy of ocrelizumab and rituximab in active multiple sclerosis.
What was tested
Treatment tested
- Rituximab
B-lymphocyte antigen CD20 binding agent
Compared with
- Ocrelizumab
B-lymphocyte antigen CD20 binding agent
What it measured
Main measures
• Percentage of patients with no new or enlarging T2 white matter lesions
MRI lesions
Other measures (1)
• Percentage of patients with 6-month confirmed disease worsening (CDW) in EDSS from baseline to month 24
Disability progression
Papers
Loading reviews and guidelines…
Related trials
- C-CAR168, an Autologous Anti-CD20/BCMA Chimeric Antigen Receptor T-Cel
Phase 1 / Phase 2 · Not yet recruiting
Still running
- IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Progressive Multi
Phase 1 · Paused
Still running
- The Effect of Rituximab on Cognitive and Hand Functions in Secondary P
Phase 2 · Recruiting
Still running
- Effect of Ocrelizumab on Choroid Plexus Changes in Patients With PPMS
Completed
No results found
- Effect of Ocrelizumab on Cortical Lesion Accumulation in Patients With
Completed
No results found
- A Study To Determine The Effect Of Ocrelizumab On Leptomeningeal Infla
Phase 4 · Withdrawn
Stopped
History
- In scope changed from true to false
Started
Jul 2020
Assembled by software from public sources.